Bioavailability of SC Formulation and Japanese Ethnobridging Study for PRA023

Phase 1 Completed 49 enrolled Prometheus Biosciences, Inc. Altasciences Company Inc. · collab

RandomizedParallel-groupDouble-blindBasic science

Summary

This is a randomized double-blind, placebo-controlled, single-dose study to evaluate the safety, tolerability, and pharmacokinetics of PRA023 in healthy Caucasian and Japanese adult volunteers

Timeline

Start: 2022-04-06
Primary completion: 2022-08-31
Completion: 2022-08-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tulisokibart	Monoclonal antibody	—	Subcutaneous

Indications

No indication recorded.